Q-omics provides the consensus-scored NDUFS4 profile across patient tissues and cancer cell-line models. NDUFS4 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, NDUFS4 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, NDUFS4 protein abundance shows 19,433 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, BLCA, and GBM as cancer lineages where NDUFS4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NDUFS4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NDUFS4 survival associations across molecular data types. NDUFS4 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NDUFS4 RNA expression–survival associations across cancer types. High NDUFS4 expression shows unfavorable associations in UVM, SCLC and KICH, but favorable associations in KIRC, READ and MESO. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for NDUFS4 RNA expression.
This table summarizes NDUFS4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NDUFS4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NDUFS4 shows lower tumor expression in BLCA, UCEC, STAD and BRCA and higher tumor expression in LIHC and KIRC. The BLCA box plot shows higher NDUFS4 RNA expression in normal versus tumor tissue (log2 FC = −0.388, t-test p < 0.001).
This table shows molecular features associated with NDUFS4 in patient tissues and cancer cell lines. In patient samples, NDUFS4 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NDUFS4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BONE.
